What is HC Wainwright’s Forecast for JSPR Q1 Earnings?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a research note issued to investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($1.48) for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q2 2025 earnings at ($1.63) EPS, Q3 2025 earnings at ($1.78) EPS, Q4 2025 earnings at ($1.93) EPS, FY2025 earnings at ($6.83) EPS, FY2026 earnings at ($8.17) EPS, FY2027 earnings at ($9.50) EPS and FY2028 earnings at ($10.61) EPS.

Other equities analysts also recently issued reports about the stock. JMP Securities reissued a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. Royal Bank of Canada dropped their price target on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a report on Thursday. Finally, BMO Capital Markets initiated coverage on Jasper Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target for the company. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics has a consensus rating of “Buy” and a consensus price target of $67.75.

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR opened at $7.05 on Monday. Jasper Therapeutics has a 52-week low of $6.57 and a 52-week high of $31.01. The business has a fifty day moving average of $21.09 and a two-hundred day moving average of $20.15. The stock has a market cap of $105.76 million, a PE ratio of -1.49 and a beta of 2.18.

Hedge Funds Weigh In On Jasper Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in JSPR. Samsara BioCapital LLC lifted its holdings in shares of Jasper Therapeutics by 11.4% during the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after purchasing an additional 59,642 shares in the last quarter. Wellington Management Group LLP acquired a new position in Jasper Therapeutics during the third quarter worth $447,000. Ally Bridge Group NY LLC grew its position in Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after purchasing an additional 180,852 shares in the last quarter. Braidwell LP bought a new position in shares of Jasper Therapeutics in the 3rd quarter valued at about $9,091,000. Finally, FMR LLC acquired a new stake in shares of Jasper Therapeutics in the third quarter valued at about $722,000. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.